Ovarian Cancer (OC)
Ovarian cancer (OC) is a significant health concern, ranking seventh among malignant tumors and the eighth leading cause of cancer-related deaths in women worldwide. At our company, we are committed to advancing effective drug and therapeutic development services to help pharmaceutical companies combat OC.
Introduction to Ovarian Cancer (OC)
Ovarian cancer, a malignancy originating in the ovaries, which are vital organs responsible for egg production and hormone synthesis, poses a significant global health burden. Annually, there are approximately 239,000 new cases and 152,000 fatalities attributed to ovarian cancer (OC). This cancer can be categorized into various subtypes, characterized by distinct histological and molecular features. The most prevalent subtype is epithelial OC, further classified into serous, endometrioid, clear cell, and mucinous tumors.
Biomarkers of Ovarian Cancer (OC)
Biomarkers play a crucial role in the diagnostics and therapy development of ovarian cancer (OC). Among these biomarkers, CA-125 is widely recognized, as it is often elevated in the blood of OC patients. However, it is important to note that CA-125 is not specific to OC and can also be elevated in other conditions. Consequently, researchers are actively exploring alternative biomarkers, including HE4, mesothelin, and OVA1, to enhance the accuracy of OC diagnosis and monitoring.
Fig.1 Biomarker development for early diagnosis of OC. (Xiao, Yinan, et al., 2022)Therapeutics Development of Ovarian Cancer (OC)
- Targets of Ovarian Cancer (OC)
Developing effective therapies for OC requires understanding the molecular targets involved in promoting tumor growth and survival. Several targets have been identified, including the PI3K/AKT/mTOR pathway, which is frequently dysregulated in OC. Other targets include VEGF, HER2, and PARP, among others. Targeted therapies that inhibit these specific molecular targets have shown promising results in research.
- Types of Ovarian Cancer (OC) Therapy
Standard therapeutic modalities encompass surgery, chemotherapy, and radiation therapy. Surgical procedures aim to excise the tumor and affected tissues, while chemotherapy employs powerful drugs to eradicate cancer cells. Radiation therapy utilizes high-energy beams to destroy malignant cells. Furthermore, ongoing research is investigating targeted therapies, immunotherapies, and hormonal therapies as potential therapeutic avenues for OC.
Fig.2 Emerging immunotherapies for ovarian cancer. (Chandra A., et al., 2019)Our Services
At our company, we specialize in the development of diagnostics and therapies specifically for ovarian cancer (OC). Our experienced team of researchers and scientists work diligently to identify novel therapeutic targets and develop innovative therapies to target OC specifically.
Therapy Development Platforms
Animal Models of Ovarian Cancer (OC)
With a professional team and experience in OC model development, we provide customized animal model development services to ensure that our customers can obtain reliable and predictable preclinical research models.
| Chemical Carcinogenesis Models | |||||
|---|---|---|---|---|---|
| At our company, we offer comprehensive carcinogen-induced model development services to aid researchers in investigating the impact of specific chemical agents on OC development. By utilizing carcinogens, we can induce the formation of ovarian tumors in animal models. | |||||
| Optional Carcinogens |
|
|
|||
| Xenograft Models | |||||
| Using OC cell lines, such as the MOSE cell line or ID8 cells, we can establish syngeneic mouse models by transplanting these cells into immunocompetent host mice. This approach allows for the study of tumor metastasis, immunological responses, and the evaluation of immunotherapy interventions. | |||||
| Optional Cells | HEY, OVCAR-3, OVCA429, OVCA433, OCC1, A2780-s, A2780-cp, SKOV-3, OV2008, C13, and ES-2 | ||||
| Genetically Engineered Models | |||||
| By manipulating genes, we can create genetically engineered mouse models (GEMMs) that closely resemble human OC. These models provide valuable insights into the molecular mechanisms underlying OC development, tumor histology, and potential therapeutic targets. | |||||
| Optional Genetic Modifications | TP53, C-MYC, K-RAS, AKT, BRCA1, and BRCA2 | ||||
| Optional Species | Mouse, Rat, Fruitfly, Laying Hen, Frog, Zebrafish, Others | ||||
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Xiao, Yinan, et al. "Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis." EBioMedicine 79 (2022).
- Chandra A, Pius C, Nabeel M, et al. "Ovarian cancer: Current status and strategies for improving therapeutic outcomes". Cancer Med. 2019 Nov;8(16):7018-7031.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
